Takes out the
thread of redness
Inhibition of the inflammatory Decrease of
effect of LL-37 skin erythema
Description
Tetrapeptide that decreases the appearance of
anti-redness facial redness and telangiectasia caused by an
exaggerated inflammatory response. telangyn™
peptide reduces the release of interleukins (IL-6
and IL-8) induced by 37-amino-acid peptide (LL-37),
cathelicidin overexpressed in skin disorders with
sensitive skin
erythema.
Appearance
Translucent solution containing 0.05% active
ingredient.
INCI
Water (Aqua), Acetyl Tetrapeptide-40, Caprylyl Glycol.
Preservative free.
Properties
telangyn™ peptide fights the undesired effects
caused by inflammation such as skin redness and
dilated blood vessels, tissue degradation as well
as post-inflammatory hyperpigmentation and dull
skin.
Applications
telangyn™ peptide can be incorporated into
formulations designed to reduce facial redness
and telangiectasia, improving even skin tone, while
providing additional firming and photoprotective
effects.
Improvement of skin
redness disorders
Science
In the natural response of the immune system to
potential harmful agents and conditions, kallikreins
and antimicrobial compounds like cathelicidins
have an important role. They induce the release of
interleukines (IL), which are among the increased
molecules in facial skin redness and vascular
alterations. In skin disorders with erythema and
dilated blood vessels, like rosacea, LL-37 expression
is found to be abnormally high, it is locally activated
and a cascade of inflammatory reactions leads to
an increase of pro-inflammatory metabolites, IL-6
and IL-8 among others.
The dermal connective tissue may be damaged
as the proteolytic degradation of the extracellular
matrix (ECM), mainly of collagen, is increased due
to Matrix Metalloproteinases (MMPs) activation.
Therefore, red areas become more visible as
capillaries are fragile and permeable, and blood
vessels can easily dilate due to inflammation.
telangyn™ peptide helps to decrease facial redness
and other skin disorders caused by LL-37 activation
and subsequent release of ILs. It also provides a
photoprotective effect lowering cell damage and
skin inflammation negative effects.
Dosage 2%
Solubility
Water soluble.
www.lipotec.com
In vitro efficacy
1. INHIBITION OF LL-37-INDUCED IL RELEASE telangyn™ peptide
The inhibition of the activity of LL-37 was measured by the release of the key pro-inflammatory lowers LL-37-mediated
cytokines IL-6 and IL-8 in human primary keratinocytes treated with LL-37 alone or with IL-6 and IL-8 release
telangyn™ peptide. Quantification was performed by ELISA. IL-6 levels decreased
by 24.2% and IL-8, by
22.8% with telangynTM
peptide at 0.5mg/ml.
2. ANTI-COLLAGENASE ASSAY Connective tissue
The anti-collagenase effect of telangyn™ peptide was evaluated by measuring the fluorescence degradation is reduced
of the fluorescein conjugate (gelatine). Fluorescence intensity is proportional to proteolytic by telangyn™ peptide
activity. telangynTM peptide
demonstrated a
statistically significant

In vivo efficacy inhibitory effect on

collagenase activity.

SKIN REDNESS IMPROVEMENT

A group of 20 volunteers (aged between 25 and 65) with healthy skin but mild rosacea
applied a cream containing 2% telangyn™ peptide solution twice a day for 28 days.

• Dermatological evaluation Erythema, redness

A trained specialist evaluated erythema, skin redness and extent intensity as well as skin and extent intensity
roughness using a scale from no intensity to maximum intensity, after 1 and 4 weeks. are reduced with
telangyn™ peptide
0 days 28 days Skin roughness diminished
0 as well, by 7.5% at the end
-2 of the treatment.
Average decrease (%)

-4
-6
-8
-10
-12
-14
-16
-17.7% -17.9%
-18
-19.2%
-20

Erythema Skin redness Extent

intensity intensity intensity

7 days 28 days

• Instrumental evaluation telangyn™ peptide

VISIA™ analysis was performed in 5 of the volunteers at the end of the treatment (4 weeks). decreases facial redness,
Feature counts are the number of red areas and absolute scores are the size and intensity reducing the number
of the red areas. of red areas as well as
their size and intensity
0
Skin redness decrease (%)

-2
-4
-6
-8
-8.3%
-10
-12
-14
-14.3%
-16

Features counts Absolute scores

The trademarks referenced in this brochure are owned by The Lubrizol Corporation. While the claims and supporting data provided in this publication are believed to be reliable and they are
presented free and for guidance only, there are no warranties of any kind. All express and implied warranties are disclaimed. The recipient is solely responsible for ensuring that products marketed
to consumers comply with all relevant laws and regulation. LIPOTEC is the exclusive holder of the both industrial and intellectual property rights identified herein. Recipient of this publication Ed. 14A
agrees to indemnify and hold harmless each entity of the LIPOTEC organization for any and all regulatory action arising from recipient’s use of any claims or information in this publication,
including, but not limited to, use in advertising and finished product label claims, and not present this publication as evidence of finished product claim substantiation to any regulatory authority. © 2014 The Lubrizol Corporation.
All Rights Reserved.
Isaac Peral 17 Pol. Industrial Camí Ral - 08850 Gavà (Barcelona) Spain-Tel +34 93 638 80 00 / Fax +34 93 638 93 93 - commercial@lipotec.com